HC Wainwright Issues Pessimistic Forecast for SLDB Earnings

Solid Biosciences Inc. (NASDAQ:SLDB) – HC Wainwright cut their Q2 2026 earnings per share (EPS) estimates for Solid Biosciences in a research note issued to investors on Wednesday, June 3rd. HC Wainwright analyst A. He now forecasts that the company will post earnings of ($0.41) per share for the quarter, down from their previous estimate of ($0.35). HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Solid Biosciences’ current full-year earnings is ($1.81) per share. HC Wainwright also issued estimates for Solid Biosciences’ Q3 2026 earnings at ($0.41) EPS, Q4 2026 earnings at ($0.41) EPS, FY2026 earnings at ($1.72) EPS, Q1 2027 earnings at ($0.42) EPS, Q2 2027 earnings at ($0.43) EPS, Q3 2027 earnings at ($0.44) EPS, Q4 2027 earnings at ($0.43) EPS, FY2027 earnings at ($1.72) EPS, FY2028 earnings at ($1.33) EPS and FY2029 earnings at $0.26 EPS.

Solid Biosciences (NASDAQ:SLDB) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.12).

Several other equities analysts have also issued reports on SLDB. Piper Sandler reissued an “overweight” rating and issued a $18.00 price target (up from $17.00) on shares of Solid Biosciences in a research note on Wednesday, May 13th. Chardan Capital reissued a “buy” rating and issued a $15.00 price target on shares of Solid Biosciences in a research note on Friday, March 20th. Wall Street Zen lowered Solid Biosciences from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th. Needham & Company LLC reiterated a “buy” rating and issued a $19.00 price target on shares of Solid Biosciences in a report on Friday, March 20th. Finally, JPMorgan Chase & Co. increased their price target on Solid Biosciences from $11.00 to $12.00 and gave the stock an “overweight” rating in a report on Wednesday, March 25th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Solid Biosciences currently has an average rating of “Moderate Buy” and an average price target of $16.82.

Solid Biosciences Stock Performance

Shares of SLDB opened at $7.24 on Friday. Solid Biosciences has a 52-week low of $3.68 and a 52-week high of $8.87. The business’s 50 day moving average price is $7.42 and its two-hundred day moving average price is $6.51. The firm has a market cap of $712.78 million, a PE ratio of -3.71 and a beta of 2.43.

Institutional Trading of Solid Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of the business. Perceptive Advisors LLC increased its position in shares of Solid Biosciences by 0.6% during the first quarter. Perceptive Advisors LLC now owns 11,906,646 shares of the company’s stock valued at $85,728,000 after acquiring an additional 73,107 shares during the last quarter. Bank of America Corp DE increased its position in shares of Solid Biosciences by 12.3% during the first quarter. Bank of America Corp DE now owns 386,793 shares of the company’s stock valued at $2,785,000 after acquiring an additional 42,499 shares during the last quarter. Stempoint Capital LP purchased a new stake in shares of Solid Biosciences during the first quarter valued at approximately $1,407,000. Janus Henderson Group PLC purchased a new stake in shares of Solid Biosciences during the first quarter valued at approximately $28,877,000. Finally, Ally Bridge Group NY LLC increased its position in shares of Solid Biosciences by 85.4% during the first quarter. Ally Bridge Group NY LLC now owns 766,974 shares of the company’s stock valued at $5,522,000 after acquiring an additional 353,349 shares during the last quarter. 81.46% of the stock is owned by hedge funds and other institutional investors.

Key Solid Biosciences News

Here are the key news stories impacting Solid Biosciences this week:

• Positive Sentiment: HC Wainwright raised its price target on Solid Biosciences to $25 and kept a Buy rating, reinforcing a bullish long-term view for reference.
• Neutral Sentiment: HC Wainwright’s updated forecasts still call for substantial losses in 2026-2028, though the firm expects the company to move toward profitability later in the decade.
• Negative Sentiment: The analyst lowered near-term EPS estimates for FY2026, FY2027, FY2028 and several quarterly periods, which could limit momentum in the stock.

Solid Biosciences Company Profile

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.